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Garrett E. Schramm, PharmD; Jennifer A. Johnson, MD;
Joshua A. Doherty, BS; Scott T. Micek, PharmD;
Marin H. Kollef, MD
The incidence of community-associated, healthcare-associated,
and hospital-acquired sterile-site infections due to methicillin-re-
sistant Staphylococcus aureus (MRSA) isolates and the susceptibility
of the isolates to non–b-lactam antibiotics were evaluated for 549
hospitalized patients during a 3-year period. The incidence of com-
munity-associated MRSA infection increased significantly. The an-
nual percentage of MRSA isolates from cases of healthcare-asso-
ciated and hospital-acquired infection that were susceptible to 3
or more non–b-lactam antibiotics increased significantly.
Infect Control Hosp Epidemiol 2007; 28:95-97
Methicillin-resistant Staphylococcus aureus (MRSA) has
moved beyond the hospital setting and is emerging as a
community-acquired pathogen among patients without es-
tablished risk factors.1 Although community-associated
MRSA (CA-MRSA) strains are primarily associated with
skin and soft tissue infections, they are increasingly the cause
of more-invasive infections, including fatal necrotizing
pneumonia.2,3 The identification of MRSA strains that orig-
inated in the community is based on a patient’s recent
healthcare exposure.4 Additionally, CA-MRSA strains have
increased susceptibility to non–b-lactam antibiotics, in-
cluding gentamicin, trimethoprim-sulfamethoxazole, fluo-
roquinolones, erythromycin, tetracylines, and clindamycin,
compared with healthcare-associated MRSA (HC-MRSA)
strains.1,5,6
We performed a retrospective cohort analysis with 3 main
goals. The first goal was to determine the incidence of CA-
MRSA, HC-MRSA, and hospital-acquired MRSA (HA-
MRSA) sterile-site infections (SSIs) in hospitalized patients
during a 3-year period. Our second goal was to evaluate the
annual susceptibility rates to 5 non–b-lactam antibiotics—
gentamicin, trimethoprim-sulfamethoxazole, erythromycin,
ciprofloxacin, and clindamycin—for each source of MRSA
infection. The third goal was to determine the annual in-
cidence of SSI due to non–multidrug resistant, oxacillin-
resistant S. aureus isolates, defined as isolates susceptible to
3 or more non–b-lactam antibiotics.7
methods
This retrospective study was conducted at Barnes-Jewish Hos-
pital at Washington University Medical Center (St. Louis,
MO), a university-affiliated, urban teaching hospital (with
1,200 beds). Hospitalized patients with sterile-site specimens
culture-positive for MRSA were evaluated during a 3-year
period (January 2002 to December 2004). An SSI was defined
as bacteremia, bronchoscopically diagnosed pneumonia, peri-
tonitis, or meningitis. All infections were categorized as com-
munity associated, healthcare associated, or hospital acquired
in origin. CA-MRSA infections were classified in accordance
with the criteria established by the Centers for Disease Con-
trol and Prevention (CDC).4 These criteria included isolation
of MRSA within 48 hours after hospitalization for patients
who had not been hospitalized, resided in a nursing home
or skilled nursing facility, or had a medical procedure (such
as dialysis, surgery, or in-dwelling catheterization) in the year
preceding isolation of MRSA and who had a medical history
that did not include MRSA infection or colonization. Health-
care-associated infections included SSIs that occurred within
48 hours after hospital admission, but with violation of 1 or
more of the above-mentioned CDC criteria that define com-
munity-associated infection. Hospital-acquired infection was
defined by isolation of MRSA after 48 hours or more after
hospitalization. At acquisition-type assignment, the MRSA
isolate’s susceptibility to 5 non–b-lactam antibiotics (genta-
micin, trimethoprim-sulfamethoxazole, erythromycin, cip-
rofloxacin, and clindamycin) was determined, and annual
susceptibility rates were compared. The presence of inducible
macrolide-lincosamide–streptogramin B resistance was not
considered in this analysis. The number of isolates that dem-
onstrated susceptibility to 3 or more non–b-lactam antibiotics
was evaluated in an attempt to quantify the incidence of non–
multidrug resistant, oxacillin-resistant S. aureus infection.7
Continuous variables were compared using the Student
t test, for normally distributed variables, and the Mann-Whit-
ney U test, for nonnormally distributed variables. The x2 or
Fisher’s exact test was used to compare categorical variables.
results
A total of 697 consecutive patients with SSI due to MRSA
were evaluated. Of these, 148 (21%) were excluded because
of incomplete information regarding healthcare status in the
year prior to the positive culture result. The remaining 549
patients comprised the study cohort. Overall, 474 (86.3%) of
the 549 isolates were obtained from culture of blood, 51
(9.3%) from culture of bronchoalveolar lavage fluid, 13
(2.4%) from culture of peritoneal fluid, and 10 (1.8%) from
culture of cerebrospinal fluid.
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table 1. Non–b-Lactam Susceptibility Among Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Ob-
tained from Hospitalized Patients
Antimicrobial








Gentamicin 35 (100) 234 (88.0) 203 (81.9) .006
Trimethoprim-sulfamethoxazole 34 (97.1) 239 (90.2) 221 (89.1) .328
Erythromycin 4 (11.4) 18 (6.8) 15 (6.0) .493
Ciprofloxacin 14 (40.0) 21 (7.9) 8 (3.2) !.001
Clindamycin 28 (80.0) 84 (31.6) 49 (19.8) !.001
table 2. Annual Incidence of Sterile-Site Infection Due to Non–
Multidrug Resistant, Oxacillin-Resistant Strains of Methicillin-
Resistant Staphylococcus aureus (MRSA)




All (n p 549) 25/166 55/194 69/189 !.001
Community-associated (n p 35) 8/8 8/8 17/19 NS
Healthcare-associated (n p 266) 10/73 29/101 36/92 .001
Hospital-acquired (n p 248) 7/85 18/85 16/78 .039
note. NS, not signficant ( ).P 1 .05
a No. of isolates with the specified resistance profile (see Methods) as a
proportion of isolates recovered from infections of the specified class.
During the 3-year period evaluated, there were 35 (6.4%)
CA-MRSA SSIs, 266 (48.5%) HC-MRSA SSIs, and 248
(45.1%) HA-MRSA SSIs. The number of CA-MRSA SSIs sig-
nificantly increased from 2002 (5%) and 2003 (5%) to 2004
(10%) ( ). Patients with CA-MRSA infection were sta-P ! .05
tistically younger ( ), were more likely to be AfricanP ! .001
American ( ), and were more likely to have a con-P ! .001
comitant skin and/or soft tissue infection ( ). MRSAP ! .001
isolates from cases of community-associated infection were
statistically more likely to be susceptible to gentamicin
( ), ciprofloxacin ( ), and clindamycin (Pp .006 P ! .001 P !
) than were isolates from cases of healthcare-associated.001
and hospital-acquired infections (Table 1). The susceptibility
of isolates from cases of CA-MRSA infection did not differ
statistically among the antibiotics evaluated from 2002 to
2004. In contrast, isolates from cases of healthcare-associated
infection demonstrated a significant increase in susceptibility
to clindamycin from 2002 to 2004 ( ). Isolates fromP ! .001
cases of hospital-aquired infection demonstrated significant
increases in susceptibility to ciprofloxacin ( ) andPp .031
clindamycin ( ) from 2002 to 2004. A significant in-Pp .011
crease in the number of non–multidrug resistant, oxacillin-
resistant S. aureus isolates from sterile sites (susceptible to 3
or more non–b-lactam antibiotics) was also observed from
2002 to 2004 ( ). A statistically significant increase inP ! .001
the number of non–multidrug resistant, oxacillin-resistant S.
aureus isolates was not observed among isolates from cases
of community associated infection but was observed among
isolates from cases of healthcare-associated ( ) andPp .001
hospital-acquired ( ) infection (Table 2).Pp .039
discussion
Our study demonstrated that the incidence of CA-MRSA SSIs
that required hospitalization increased significantly during the
3-year study period. Additionally, the number of isolates from
cases of HC-MRSA and HA-MRSA infection with suscep-
tibility to 3 or more non–b-lactam antibiotics (ie, non–mul-
tidrug resistant, oxacillin-resistant S. aureus isolates) signifi-
cantly increased, generally as a result of improved sensitivity
to clindamycin and ciprofloxacin from 2002 to 2004.
Consistent with our findings, isolates from cases of CA-
MRSA infection have been found to have increased suscep-
tiblity to non–b-lactam antibiotics, including ciprofloxacin,
clindamycin, gentamicin, and trimethoprim-sulfamethoxa-
zole, compared with that of isolates from cases of HC-MRSA
infection.1,5,6 Simultaneous susceptibility to these non–b-lac-
tam antibiotics has been found to be an independent pre-
dictor of being infected with a CA-MRSA strain.5 Addition-
ally, the trend of non–multidrug resistant, oxacillin resistant
S. aureus isolates as an increasing cause of healthcare-asso-
ciated or hospital-acquired infections and, specifically in our
study, SSIs has been recently reported.8
Our study has several important limitations. First is the
study’s retrospective design. As such, included and excluded
patients could have been misclassified because of a lack of
documented information. It is possible that patients classified
as having CA-MRSA infected could actually have had HC-
MRSA infection, and vice versa. However, more than 90%
of the isolates from cases of CA-MRSA infection in the study
demonstrated susceptibility to non–b-lactam antibiotics,
making false-positive results unlikely. Second, our microbi-
ology laboratory did not test tetracycline susceptibility or test
for inducible macrolide-lincosamide–streptogramin B resis-
tance. The susceptibility rates for clindamycin in our study
may have been falsely elevated in the clinical sense.9,10 Third,
we did not perform genetic staphylococcal chromosomal cas-
sette (SCC) mec typing or test for genes that encode virulence
factors, such as Panton-Valentine leukocidin. However, trials
increase in ssis due to oxacillin-resistant s. aureus 97
that have performed molecular typing of non–multidrug re-
sistant, oxacillin-resistant S. aureus isolates have found the
strains to be predominately SCCmec type IV.7,11-14 Conse-
quently, an antimicrobial profile with susceptibility to mul-
tiple non–b-lactam antibiotics could be used as a phenotypic
marker for community-type strains and the possibility that
the organism produces potentially lethal toxins.2,3,15
Despite these limitations of our study, the larger point is
to reinforce the evidence that incidence of CA-MRSA SSIs
that require hospitalization is increasing, as well as to rec-
ognize that there are HC-MRSA isolates that are susceptible
to multiple non–b-lactam antibiotics. Clinicians should be
cognizant of a susceptibility profile that indicates a non–
multidrug resistant, oxacillin-resistant S. aureus isolate when
they are selecting antimicrobial therapy for healthcare-asso-
ciated infections.
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